Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 26 of 26 · 1218 articles
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Mirikizumab. The original article is from firstwordpharma.com.
Cure8 could only read part of this source from endpts.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.
Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full details.
Cure8 found this source from wsj.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Medications. Open the original article for the full details.
Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.
Cure8 found this source from reuters.com, but the page could not be read reliably yet. It is tagged for Medications. Open the original article for the full details.
This expands U.S. treatment options: Omvoh (mirikizumab) is now FDA‑approved for both major forms of IBD (ulcerative colitis and Crohn's disease), which may matter for people who haven’t responded to other therapies. The...
Patients with Crohn’s disease and other IBD forms may see new research directions aimed at blocking immune cell proliferation by targeting nucleotide metabolism. This is early-stage, preclinical work presented at a...
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Vedolizumab, and Anti Integrin. The original article is from msn.com.
Cure8 found this source from ktbs.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.
Fatigue is common in people with Crohn’s disease and ulcerative colitis and can persist even when standard measures say the disease is in remission. This study suggests stricter definitions of remission don’t necessarily...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease and Medications. The original article is from msn.com.
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from webmd.com.
If your Crohn’s gets worse, your care plan may change — from new medicines to nutritional support or surgery — and this article summarizes common steps doctors take to prevent complications and control inflammation.
Postoperative recurrence after ileocolonic resection is common in Crohn’s disease. This randomized trial suggests vedolizumab can reduce early endoscopic recurrence, offering an additional biologic option for preventing...
Perianal fistula complications are serious and difficult to treat. This study suggests starting anti-TNFα therapy early in pediatric Crohn disease may substantially lower the risk of developing these complications,...
